Recombinant human erythropoietin corrects anemia of blood loss: a study in the dog.
In order to evaluate the possibility of using recombinant human erythropoietin (rhEpo) for the prevention and correction of anemia due to blood loss and as an adjuvant for autologous blood transfusion, its preventive and therapeutic effects were evaluated in beagles in which anemia was induced by repeated phlebotomies. Two hundred U/kg of rhEpo were administered i.v. four or nine times every two weeks for six weeks. Phlebotomies (25 ml/kg of body weight) were conducted three times at two-week intervals. rhEpo was found to successfully prevent and correct anemia caused by the phlebotomies. Concurrent administration of iron increased efficacy. The findings obtained in the present study suggest that rhEpo is useful both for the treatment of anemia caused by blood loss due to surgery and as an adjuvant therapy for pre-deposit autologous blood transfusion.
Koumegawa
J
J
Pharmaceuticals Department, Kirin Brewery Co., Ltd., Tokyo, Japan.
Kawahara
J
J
Kubo
K
K
Amano
K
K
Wakimoto
N
N
Takahashi
K
K
Juji
T
T
Takaku
F
F
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000818:Animals; D004285:Dogs; D004359:Drug Therapy, Combination; D004906:Erythrocyte Count / Q000187:drug effects; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006470:Hemorrhage / Q000150:complications; D006801:Humans; D007501:Iron / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron